Physician profile
Natasha Smith
NPI 1922507581
$1,868.62
in general payments reported to CMS, 2019-2025
19 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $261 · 2022: $243 · 2023: $620 · 2024: $445 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $306.10 | 2022-2024 | Tremfya, Remicade, Stelara |
| Mallinckrodt Hospital Products INC. | $302.86 | 2022-2024 | Acthar |
| Glaxosmithkline, LLC. | $293.00 | 2021-2025 | Benlysta |
| Lilly USA, LLC | $279.86 | 2021-2023 | Taltz |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $225.84 | 2023-2025 | Lifevest |
| Pfizer INC. | $108.97 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $107.41 | 2021-2024 | Strensiq |
| Melinta Therapeutics, LLC | $46.77 | 2023-2025 | Kimyrsa |
| Mylan Institutional INC. | $25.91 | 2023 | Hulio |
| Janssen Pharmaceuticals, INC | $22.41 | 2022 | |
| Fidia Pharma USA INC. | $22.06 | 2024 | Hyalgan |
| La Jolla Pharmaceutical Company | $21.59 | 2025 | Xacduro |
| Abbvie INC. | $21.51 | 2021 | |
| Atland Pharmaceuticals, LLC | $20.58 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Paratek Pharmaceuticals, INC. | $18.65 | 2023 | Nuzyra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $15.79 | 2024 | Lupkynis |
| Allergan, INC. | $12.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.16 | 2021 | |
| Genentech USA, INC. | $5.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.